We therefore hypothesize that mGluR2/3 agonist, used as a non-dopaminergic antipsychotic drug for treatment of schizophrenia [3], [26], might directly affect the expression and/or trafficking of AMPA receptors in the postsynaptic site. This evidence concerns the gene GRM2 and schizophrenia.